{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:21:55Z","timestamp":1793701315542,"version":"4.5.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Centre for Higher Education Funding (BPPT) Ministry of Education, Culture, Research and Technology of the Republic of Indonesia and The Indonesia Endowment Fund for Education","award":["202101182687"],"award-info":[{"award-number":["202101182687"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["WT 206331\/Z\/17\/Z"],"award-info":[{"award-number":["WT 206331\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute for Health and Care Research, Oxford Biomedical Research Centre"},{"name":"University of Oxford, Medical and Life Sciences Translational Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>BCG remains the only licensed vaccine for tuberculosis (TB), but its efficacy wanes over time. Subunit vaccines, aim to improve BCG immunity and protection, by inducing responses to a few mycobacterial antigens delivered with a specific platform. Since the platform shapes the immune response induced, selecting the right platform has been challenging due to the lack of immune correlates of protection. Recently, the protein-adjuvated subunit vaccine. M72\/AS01E, demonstrated 49.7% efficacy in preventing active TB in latently infected adults, indicating that protective immunity through subunit vaccines is possible. In this study we evaluated the immunogenicity and efficacy of the promising mycobacterial antigen PPE15, formulated with five adjuvants developed by the Vaccine Formulation Institute. While all adjuvants were immunogenic, PPE15 with LMQ protected vaccinated mice against an in vivo <jats:italic>Mycobacterium tuberculosis<\/jats:italic> challenge, both as a standalone vaccine and as a boost to BCG. Vaccinated mice had enriched lung parenchymal antigen-specific CD4\u2009+\u2009CXCR3\u2009+\u2009KLRG1\u2212 T cells previously associated with TB protection. Heterologous vaccination strategies were also explored by combining intranasal ChAdOx1.PPE15 viral vector, with intramuscular PPE15-LMQ resulting in improved protection compared to individual vaccines. These findings support the progression of this vaccine candidate to the next stages of development.<\/jats:p>","DOI":"10.1038\/s41598-024-84667-8","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:52:10Z","timestamp":1736808730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate"],"prefix":"10.1038","volume":"15","author":[{"given":"Marcellus","family":"Korompis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"De Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuailin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem Salman","family":"Almujri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Ateere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stylianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"84667_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2023 (World Health Organization, 2023)."},{"key":"84667_CR2","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange, C. et al. 100 years of Mycobacterium bovis Bacille Calmette-Gu\u00e9rin. Lancet. Infect. Dis. 22, e2\u2013e12 (2022).","journal-title":"Lancet. Infect. Dis."},{"key":"84667_CR3","unstructured":"Fine, P. E., Carneiro, I. A., Milstien, J. B., Clements, C. J. & Organization, W. H. Issues Relating to the use of BCG in Immunization Programmes: A Discussion Document (World Health Organization, 1999)."},{"key":"84667_CR4","doi-asserted-by":"publisher","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","volume":"10","author":"L Martinez","year":"2022","unstructured":"Martinez, L. et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob. Health 10, e1307\u2013e1316 (2022).","journal-title":"Lancet Glob. Health"},{"key":"84667_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1098\/rstb.2011.0097","volume":"366","author":"H McShane","year":"2011","unstructured":"McShane, H. Tuberculosis vaccines: beyond Bacille Calmette-Guerin. Philos. Trans. R Soc. Lond. B Biol. Sci. 366, 2782\u20132789 (2011).","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"84667_CR6","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance (World Health Organization, 2024)."},{"key":"84667_CR7","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait, D. R. et al. Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429\u20132439 (2019).","journal-title":"N. Engl. J. Med."},{"key":"84667_CR8","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1128\/IAI.00827-15","volume":"83","author":"S Shah","year":"2015","unstructured":"Shah, S., Cannon, J. R., Fenselau, C. & Briken, V. A duplicated ESAT-6 region of ESX-5 is involved in protein export and virulence of mycobacteria. Infect. Immun. 83, 4349\u20134361 (2015).","journal-title":"Infect. Immun."},{"key":"84667_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/mmi.13422","volume":"101","author":"J Daniel","year":"2016","unstructured":"Daniel, J., Kapoor, N., Sirakova, T., Sinha, R. & Kolattukudy, P. The perilipin-like PPE15 protein in Mycobacterium tuberculosis is required for triacylglycerol accumulation under dormancy\u2010inducing conditions. Mol. Microbiol. 101, 784\u2013794 (2016).","journal-title":"Mol. Microbiol."},{"key":"84667_CR10","doi-asserted-by":"publisher","first-page":"119702","DOI":"10.1016\/j.bbamcr.2024.119702","volume":"1871","author":"Priyanka","year":"2024","unstructured":"Priyanka et al. Mycobacterium tuberculosis protein PPE15 (Rv1039c) possesses eukaryote-like SH3 domain that interferes with NADPH oxidase assembly and reactive oxygen species production. Biochim. Biophys. Acta Mol. Cell. Res. 1871, 119702 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"84667_CR11","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1371\/journal.ppat.0030127","volume":"3","author":"DA Lewinsohn","year":"2007","unstructured":"Lewinsohn, D. A. et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog. 3, e127 (2007).","journal-title":"PLoS Pathog."},{"key":"84667_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41541-017-0008-6","volume":"2","author":"DA Lewinsohn","year":"2017","unstructured":"Lewinsohn, D. A. et al. Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. NPJ Vaccines 2, 8 (2017).","journal-title":"NPJ Vaccines"},{"key":"84667_CR13","doi-asserted-by":"publisher","first-page":"e00014","DOI":"10.1128\/IAI.00014-18","volume":"86","author":"E Stylianou","year":"2018","unstructured":"Stylianou, E. et al. Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infect. Immun. 86, e00014\u2013e00018 (2018).","journal-title":"Infect. Immun."},{"key":"84667_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2023.1263457","volume":"14","author":"E Stylianou","year":"2023","unstructured":"Stylianou, E. et al. A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M. tb challenge. Front. Immunol. 14, 1 (2023).","journal-title":"Front. Immunol."},{"key":"84667_CR15","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1016\/j.vaccine.2011.04.125","volume":"29","author":"N Collin","year":"2011","unstructured":"Collin, N. & Dubois, P. M. The vaccine formulation laboratory: a platform for access to adjuvants. Vaccine 29, A37\u2013A39 (2011).","journal-title":"Vaccine"},{"key":"84667_CR16","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.vaccine.2023.03.035","volume":"41","author":"S Xu","year":"2023","unstructured":"Xu, S. et al. Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE\u2122. Vaccine 41, 2793\u20132803 (2023).","journal-title":"Vaccine"},{"key":"84667_CR17","doi-asserted-by":"publisher","first-page":"101245","DOI":"10.1016\/j.xcrm.2023.101245","volume":"4","author":"S Reinke","year":"2023","unstructured":"Reinke, S. et al. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell. Rep. Med. 4, 101245 (2023).","journal-title":"Cell. Rep. Med."},{"key":"84667_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.976968","volume":"13","author":"JS O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell, J. S. et al. Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Front. Immunol. 13, 1 (2022).","journal-title":"Front. Immunol."},{"key":"84667_CR19","doi-asserted-by":"publisher","unstructured":"Rivera-Hernandez, T. et al. Vaccine-induced Th1-type response protects against invasive group A Streptococcus infection in the absence of opsonizing antibodies. MBio 11, 122. https:\/\/doi.org\/10.1128\/mbio.00122-00120 (2020).","DOI":"10.1128\/mbio.00122-00120"},{"key":"84667_CR20","doi-asserted-by":"publisher","first-page":"918629","DOI":"10.3389\/fcimb.2022.918629","volume":"12","author":"T Techawiwattanaboon","year":"2022","unstructured":"Techawiwattanaboon, T. et al. Designing adjuvant formulations to promote immunogenicity and protective efficacy of leptospira immunoglobulin-like protein A subunit vaccine. Front. Cell Infect. Microbiol. 12, 918629 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"84667_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41541-023-00759-y","volume":"8","author":"S Doss-Gollin","year":"2023","unstructured":"Doss-Gollin, S. et al. Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen. NPJ Vaccines 8, 163 (2023).","journal-title":"NPJ Vaccines"},{"key":"84667_CR22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fimmu.2017.01262","volume":"8","author":"DA Lewinsohn","year":"2017","unstructured":"Lewinsohn, D. A., Lewinsohn, D. M. & Scriba, T. J. Polyfunctional CD4(+) T cells as targets for tuberculosis vaccination. Front. Immunol. 8, 1262 (2017).","journal-title":"Front. Immunol."},{"key":"84667_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.869057","volume":"13","author":"DM Lewinsohn","year":"2022","unstructured":"Lewinsohn, D. M. & Lewinsohn, D. A. The missing link in correlates of protective tuberculosis immunity: recognizing the infected cell. Front. Immunol. 13, 1 (2022).","journal-title":"Front. Immunol."},{"key":"84667_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1355983","volume":"15","author":"H Painter","year":"2024","unstructured":"Painter, H., Harriss, E., Fletcher, H. A., McShane, H. & Tanner, R. Development and application of the direct mycobacterial growth inhibition assay: a systematic review. Front. Immunol. 15, 1 (2024).","journal-title":"Front. Immunol."},{"key":"84667_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tube.2013.12.006","volume":"94","author":"HC Poyntz","year":"2014","unstructured":"Poyntz, H. C. et al. Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 94, 226\u2013237 (2014).","journal-title":"Tuberculosis (Edinb.)"},{"key":"84667_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41423-022-00861-6","volume":"19","author":"F Dieli","year":"2022","unstructured":"Dieli, F. & Ivanyi, J. Role of antibodies in vaccine-mediated protection against tuberculosis. Cell Mol. Immunol. 19, 758\u2013760 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"84667_CR27","first-page":"120","volume":"54","author":"J Tannenbaum","year":"2015","unstructured":"Tannenbaum, J. & Bennett, B. T. Russell and Burch\u2019s 3Rs then and now: the need for clarity in definition and purpose. J. Am. Assoc. Lab. Anim. Sci. 54, 120\u2013132 (2015).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"84667_CR28","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","volume":"192","author":"S Sakai","year":"2014","unstructured":"Sakai, S. et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J. Immunol. 192, 2965\u20132969 (2014).","journal-title":"J. Immunol."},{"key":"84667_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah, P. A. et al. Prevention of Tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95\u2013102 (2020).","journal-title":"Nature"},{"key":"84667_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41385-021-00461-z","volume":"15","author":"MZM Zheng","year":"2022","unstructured":"Zheng, M. Z. M. & Wakim, L. M. Tissue resident memory T cells in the respiratory tract. Mucosal Immunol. 15, 379\u2013388 (2022).","journal-title":"Mucosal Immunol."},{"key":"84667_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-27063-4","volume":"12","author":"D Lapuente","year":"2021","unstructured":"Lapuente, D. et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat. Commun. 12, 1 (2021).","journal-title":"Nat. Commun."},{"key":"84667_CR32","doi-asserted-by":"publisher","first-page":"eaap9128","DOI":"10.1126\/scitranslmed.aap9128","volume":"10","author":"A Gola","year":"2018","unstructured":"Gola, A. et al. Prime and target immunization protects against liver-stage malaria in mice. Sci. Transl. Med. 10, eaap9128 (2018).","journal-title":"Sci. Transl. Med."},{"key":"84667_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41541-023-00750-7","volume":"8","author":"R Lai","year":"2023","unstructured":"Lai, R., Ogunsola, A. F., Rakib, T. & Behar, S. M. Key advances in vaccine development for tuberculosis\u2014success and challenges. NPJ Vaccines 8, 158 (2023).","journal-title":"NPJ Vaccines"},{"key":"84667_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41541-024-01004-w","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang, J., Fan, X. Y. & Hu, Z. Immune correlates of protection as a game changer in Tuberculosis vaccine development. NPJ Vaccines 9, 208 (2024).","journal-title":"NPJ Vaccines"},{"key":"84667_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S2213-2600(19)30274-7","volume":"7","author":"H McShane","year":"2019","unstructured":"McShane, H. Insights and challenges in Tuberculosis vaccine development. Lancet Respir. Med. 7, 810\u2013819 (2019).","journal-title":"Lancet Respir. Med."},{"key":"84667_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(22)00073-1","volume":"22","author":"P Venkatesan","year":"2022","unstructured":"Venkatesan, P. Worrying lack of funding for tuberculosis. Lancet. Infect. Dis. 22, 318 (2022).","journal-title":"Lancet. Infect. Dis"},{"key":"84667_CR37","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S1473-3099(21)00810-0","volume":"22","author":"F Cobelens","year":"2022","unstructured":"Cobelens, F. et al. Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infect. Dis. 22, e108\u2013e120 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"84667_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","volume":"7","author":"M Wang","year":"2016","unstructured":"Wang, M., Jiang, S. & Wang, Y. Recent advances in the production of recombinant subunit vaccines in Pichia pastoris. Bioengineered 7, 155\u2013165 (2016).","journal-title":"Bioengineered"},{"key":"84667_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","volume":"178","author":"F Bayani","year":"2023","unstructured":"Bayani, F. et al. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. Prog. Biophys. Mol. Biol. 178, 32\u201349 (2023).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"84667_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","volume":"23","author":"F Roman","year":"2024","unstructured":"Roman, F. et al. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev. Vaccines 23, 715\u2013729 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"84667_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/cmi.2017.113","volume":"15","author":"G Zeng","year":"2018","unstructured":"Zeng, G., Zhang, G. & Chen, X. Th1 cytokines, true functional signatures for protective immunity against TB? Cell Mol. Immunol. 15, 206\u2013215 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"84667_CR42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3390\/biomedicines9070724","volume":"9","author":"CY Lo","year":"2021","unstructured":"Lo, C. Y. et al. Increased Th1 cells with disease resolution of active pulmonary tuberculosis in non-atopic patients. Biomedicines 9, 724 (2021).","journal-title":"Biomedicines"},{"key":"84667_CR43","doi-asserted-by":"crossref","unstructured":"Lyadova, I. V. & Panteleev, A. V. Th1 and Th17 cells in tuberculosis: Protection, pathology, and biomarkers. Mediat. Inflamm. 2015, 854507 (2015).","DOI":"10.1155\/2015\/854507"},{"key":"84667_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/vaccines8020300","volume":"8","author":"HG Choi","year":"2020","unstructured":"Choi, H. G. et al. Antigen-specific IFN-\u03b3\/IL-17-co-producing CD4\u2009+\u2009T-cells are the determinants for protective efficacy of tuberculosis subunit vaccine. Vaccines 8, 300 (2020).","journal-title":"Vaccines"},{"key":"84667_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/clinpract12050082","volume":"12","author":"G Shanmuganathan","year":"2022","unstructured":"Shanmuganathan, G. et al. Role of interferons in Mycobacterium tuberculosis infection. Clin. Pract. 12, 788\u2013796 (2022).","journal-title":"Clin. Pract."},{"key":"84667_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0008-8749(02)00510-5","volume":"216","author":"BM Saunders","year":"2002","unstructured":"Saunders, B. M., Frank, A. A., Orme, I. M. & Cooper, A. M. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell. Immunol. 216, 65\u201372 (2002).","journal-title":"Cell. Immunol."},{"key":"84667_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/cimm.2001.1819","volume":"211","author":"JE Pearl","year":"2001","unstructured":"Pearl, J. E., Saunders, B., Ehlers, S., Orme, I. M. & Cooper, A. M. Inflammation and lymphocyte activation during mycobacterial infection in the interferon-\u03b3-Deficient mouse. Cell. Immunol. 211, 43\u201350 (2001).","journal-title":"Cell. Immunol."},{"key":"84667_CR48","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","volume":"178","author":"AM Cooper","year":"1993","unstructured":"Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243\u20132247 (1993).","journal-title":"J. Exp. Med."},{"key":"84667_CR49","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/clinids\/22.4.671","volume":"22","author":"JE Gallant","year":"1996","unstructured":"Gallant, J. E. & Ko, A. H. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 22, 671\u2013682 (1996).","journal-title":"Clin. Infect. Dis."},{"key":"84667_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.vaccine.2014.11.013","volume":"33","author":"A Cruz","year":"2015","unstructured":"Cruz, A. et al. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4\u207aIL-17\u207aTNF\u207aIL-2\u207a T cells. Vaccine 33, 85\u201391 (2015).","journal-title":"Vaccine"},{"key":"84667_CR51","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/infdis\/jiv503","volume":"213","author":"N Aguilo","year":"2015","unstructured":"Aguilo, N. et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17\u2013dependent mechanism. J. Infect. Dis. 213, 831\u2013839 (2015).","journal-title":"J. Infect. Dis."},{"key":"84667_CR52","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3390\/cells11182875","volume":"11","author":"K Ritter","year":"2022","unstructured":"Ritter, K. et al. High-dose Mycobacterium tuberculosis H37rv infection in IL-17A- and IL-17A\/F-deficient mice. Cells 11, 2875 (2022).","journal-title":"Cells"},{"key":"84667_CR53","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","volume":"184","author":"Y Okamoto Yoshida","year":"2010","unstructured":"Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 184, 4414\u20134422 (2010).","journal-title":"J. Immunol."},{"key":"84667_CR54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","volume":"21","author":"E Torrado","year":"2010","unstructured":"Torrado, E. & Cooper, A. M. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor. Rev. 21, 455\u2013462 (2010).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"84667_CR55","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"84667_CR56","doi-asserted-by":"publisher","first-page":"1102524","DOI":"10.3389\/fimmu.2023.1102524","volume":"14","author":"CR Alving","year":"2023","unstructured":"Alving, C. R., Rao, M. & Matyas, G. R. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21. Front. Immunol. 14, 1102524 (2023).","journal-title":"Front. Immunol."},{"key":"84667_CR57","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., Arunachalam, S., O\u2019Hagan, D. T. & P. & Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"84667_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal. Transduct. Target. Ther. 8, 283 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"84667_CR59","doi-asserted-by":"publisher","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","volume":"60","author":"MA Lacaille-Dubois","year":"2019","unstructured":"Lacaille-Dubois, M. A. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine 60, 152905 (2019).","journal-title":"Phytomedicine"},{"key":"84667_CR60","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","volume":"5","author":"C Pifferi","year":"2021","unstructured":"Pifferi, C., Fuentes, R. & Fern\u00e1ndez-Tejada, A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat. Rev. Chem. 5, 197\u2013216 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"84667_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/pharmaceutics8010007","volume":"8","author":"S Tandrup Schmidt","year":"2016","unstructured":"Tandrup Schmidt, S., Foged, C., Smith Korsholm, S., Rades, T. & Christensen, D.  Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 8, 7 (2016).","journal-title":"Pharmaceutics"},{"key":"84667_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","volume":"303","author":"N Wang","year":"2019","unstructured":"Wang, N., Chen, M. & Wang, T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J. Controlled Release 303, 130\u2013150 (2019).","journal-title":"J. Controlled Release"},{"key":"84667_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfimm\/iqab015","volume":"2","author":"C Hermann","year":"2021","unstructured":"Hermann, C. & King, C. G. TB or not to be: what specificities and impact do antibodies have during tuberculosis? Oxf. Open Immunol. 2, 1 (2021).","journal-title":"Oxf. Open Immunol."},{"key":"84667_CR64","doi-asserted-by":"publisher","first-page":"107944","DOI":"10.1016\/j.exppara.2020.107944","volume":"216","author":"S Nazeri","year":"2020","unstructured":"Nazeri, S., Zakeri, S., Mehrizi, A. A., Sardari, S. & Djadid, N. D. Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with Plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response. Exp. Parasitol. 216, 107944 (2020).","journal-title":"Exp. Parasitol."},{"key":"84667_CR65","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1128\/IAI.68.4.2102-2109.2000","volume":"68","author":"N Ahlborg","year":"2000","unstructured":"Ahlborg, N., Ling, I. T., Holder, A. A. & Riley, E. M. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Infect. Immun. 68, 2102\u20132109 (2000).","journal-title":"Infect. Immun."},{"key":"84667_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41541-020-00263-7","volume":"6","author":"R Tanner","year":"2021","unstructured":"Tanner, R. et al. A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates. NPJ Vaccines 6, 3 (2021).","journal-title":"NPJ Vaccines"},{"key":"84667_CR67","doi-asserted-by":"crossref","unstructured":"Li, W., Deng, G., Li, M., Liu, X. & Wang, Y. Roles of mucosal immunity against Mycobacterium tuberculosis infection. Tuberc. Res. Treat. 2012, 791728 (2012).","DOI":"10.1155\/2012\/791728"},{"key":"84667_CR68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mi.2016.70","volume":"10","author":"JS Woodworth","year":"2017","unstructured":"Woodworth, J. S. et al. Subunit vaccine H56\/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung. Mucosal Immunol. 10, 555\u2013564 (2017).","journal-title":"Mucosal Immunol."},{"key":"84667_CR69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-019-0113-9","volume":"4","author":"PA Darrah","year":"2019","unstructured":"Darrah, P. A. et al. Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques. NPJ Vaccines 4, 21 (2019).","journal-title":"NPJ Vaccines"},{"key":"84667_CR70","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.vaccine.2021.01.034","volume":"39","author":"N Pinpathomrat","year":"2021","unstructured":"Pinpathomrat, N. et al. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. Vaccine 39, 1452\u20131462 (2021).","journal-title":"Vaccine"},{"key":"84667_CR71","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4049\/jimmunol.1301161","volume":"191","author":"SL Baldwin","year":"2013","unstructured":"Baldwin, S. L. et al. Protection against Tuberculosis with homologous or heterologous protein\/vector vaccine approaches is not dependent on CD8\u2009+\u2009T cells. J. Immunol. 191, 2514\u20132525 (2013).","journal-title":"J. Immunol."},{"key":"84667_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23173-1","volume":"12","author":"AJ Spencer","year":"2021","unstructured":"Spencer, A. J. et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat. Commun. 12, 1 (2021).","journal-title":"Nat. Commun."},{"key":"84667_CR73","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14760584.2019.1692657","volume":"18","author":"E Stylianou","year":"2019","unstructured":"Stylianou, E., Paul, M. J., Reljic, R. & McShane, H. Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. Expert Rev. Vaccines 18, 1271\u20131284 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"84667_CR74","doi-asserted-by":"publisher","first-page":"101408","DOI":"10.1016\/j.coviro.2024.101408","volume":"66","author":"E Stylianou","year":"2024","unstructured":"Stylianou, E. & Satti, I. Inhaled aerosol viral-vectored vaccines against tuberculosis. Curr. Opin. Virol. 66, 101408 (2024).","journal-title":"Curr. Opin. Virol."},{"key":"84667_CR75","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1128\/IAI.05048-11","volume":"79","author":"L\u00c9M Bouillet","year":"2011","unstructured":"Bouillet, L. \u00c9. M. et al. Long-term humoral and cellular immune responses elicited by a heterologous plasmodium vivax apical membrane antigen 1 protein prime\/adenovirus boost immunization protocol. Infect. Immun. 79, 3642\u20133652 (2011).","journal-title":"Infect. Immun."},{"key":"84667_CR76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1365-2567.2011.03525.x","volume":"135","author":"MJ Cayabyab","year":"2012","unstructured":"Cayabyab, M. J., Kashino, S. S. & Campos-Neto, A. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA\/protein heterologous prime\/boost protocol. Immunology 135, 216\u2013225 (2012).","journal-title":"Immunology"},{"key":"84667_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02075","volume":"10","author":"S Haddadi","year":"2019","unstructured":"Haddadi, S. et al. Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T cells. Front. Immunol. 10, 1 (2019).","journal-title":"Front. Immunol."},{"key":"84667_CR78","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1126\/science.1184784","volume":"328","author":"DG Russell","year":"2010","unstructured":"Russell, D. G., Barry, C. E., Flynn, J. L. & Tuberculosis What we don\u2019t know can, and does, hurt us. Science 328, 852\u2013856 (2010).","journal-title":"Science"},{"key":"84667_CR79","doi-asserted-by":"publisher","first-page":"e1011825","DOI":"10.1371\/journal.ppat.1011825","volume":"19","author":"CR Plumlee","year":"2023","unstructured":"Plumlee, C. R. et al. Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine model. PLoS Pathog. 19, e1011825 (2023).","journal-title":"PLoS Pathog."},{"key":"84667_CR80","doi-asserted-by":"publisher","first-page":"23308","DOI":"10.1038\/s41598-021-02442-5","volume":"11","author":"B Khatri","year":"2021","unstructured":"Khatri, B. et al. Efficacy and immunogenicity of different BCG doses in BALB\/c and CB6F1 mice when challenged with H37Rv or Beijing HN878. Sci. Rep. 11, 23308 (2021).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84667-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:36:09Z","timestamp":1736811369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84667"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84667-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1886"}}